A Look At Erasca (ERAS) Valuation After Its Strong Recent Share Price Rally

Understanding Erasca’s Recent Share Performance

Erasca (ERAS) has drawn fresh attention after a strong recent run in its share price, with the stock showing gains over the past week, month, past 3 months, and year to date.

For context, Erasca is a clinical-stage precision oncology company focused on therapies targeting RAS/MAPK pathway-driven cancers. This is a niche that often attracts investors who track early-stage biotech pipelines and clinical milestones.

See our latest analysis for Erasca.

The recent surge in Erasca’s share price, including a 90 day share price return of 300% and a very large 1 year total shareholder return, suggests momentum is building even after a 4.3% one day pullback to US$14.60.

If Erasca’s move has caught your eye, this can be a good moment to see what else is moving in healthcare AI and precision medicine via 35 healthcare AI stocks

With a 300% 90 day return, a very large 1 year total shareholder return and a recent pullback to US$14.60, the question is whether Erasca is still mispriced or if the market is already taking future growth into account.

Most Popular Narrative: 26.3% Overvalued

Vestra’s widely followed narrative pegs Erasca’s fair value at $11.56, which sits below the last close at $14.60. This sets up a valuation tension that hinges on upcoming clinical results.

The operational narrative for Erasca in 2026 is defined by the upcoming H1 2026 Phase 1 monotherapy data for ERAS-0015. Early "teasers" released in January 2026 already confirmed partial responses in multiple tumor types at doses as low as 8 mg, sparking the massive year-to-date rally.

Read the complete narrative.

Curious how a company with no current revenue, ongoing losses, and high trial expectations still lands on an $11.56 fair value? The answer hinges on projected market size, timing of potential data readouts, and how much of that upside is already baked into today’s price. The full narrative breaks down those assumptions and shows how they feed into the discount rate and long term market cap that sit behind that figure.

Result: Fair Value of $11.56 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that story can change quickly if upcoming ERAS-0015 data underwhelms or if a competing RAS program posts clearly superior results and pulls attention away.

Find out about the key risks to this Erasca narrative.

Next Steps

With all this mixed sentiment in mind, act quickly and review the numbers, risks, and narrative yourself, starting with these 4 important warning signs.

Looking For More Investment Ideas?

If Erasca has sharpened your focus, do not stop here. Use Simply Wall Street’s tools to quickly spot other opportunities that match your style before they move.

• Target income first by reviewing companies in the 13 dividend fortresses that may suit investors who want yield at the center of their portfolio.
• Pursue quality at a discount with the 53 high quality undervalued stocks to see which stocks currently show strong fundamentals at prices that may look appealing.
• Protect your capital by starting with the 67 resilient stocks with low risk scores and focusing on businesses that carry lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com